Canlyniadau Chwilio - Ken H. Young

Mireinio'r Canlyniadau
  1. 1
    Checkpoint inhibitors in hematological malignancies

    Checkpoint inhibitors in hematological malignancies gan Chi Young Ok, Ken H. Young

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Epstein–Barr virus-positive T/NK-cell lymphoproliferative disorders

    Epstein–Barr virus-positive T/NK-cell lymphoproliferative disorders gan Qingqing Cai, Kailin Chen, Ken H. Young

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    The PTEN tumor suppressor gene and its role in lymphoma pathogenesis

    The PTEN tumor suppressor gene and its role in lymphoma pathogenesis gan Xiaoxiao Wang, Huiqiang Huang, Ken H. Young

    Cyhoeddwyd 2015
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment

    Primary Central Nervous System Lymphoma: Molecular Pathogenesis and Advances in Treatment gan Qingqing Cai, Fang Yu, Ken H. Young

    Cyhoeddwyd 2019
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    New agents and regimens for diffuse large B cell lymphoma

    New agents and regimens for diffuse large B cell lymphoma gan Liang Wang, Linrong Li, Ken H. Young

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management

    EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management gan Chi Young Ok, Ling Li, Ken H. Young

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies

    Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies gan Yi Xia, L. Jeffrey Medeiros, Ken H. Young

    Cyhoeddwyd 2015
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine

    Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine gan Ruifang Sun, L. Jeffrey Medeiros, Ken H. Young

    Cyhoeddwyd 2016
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma

    Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma gan Jun Zhang, L. Jeffrey Medeiros, Ken H. Young

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Genetic lesions in diffuse large B-cell lymphomas

    Genetic lesions in diffuse large B-cell lymphomas gan Monica Testoni, Emanuele Zucca, Ken H. Young, Francesco Bertoni

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    PD-1 expression and clinical PD-1 blockade in B-cell lymphomas

    PD-1 expression and clinical PD-1 blockade in B-cell lymphomas gan Zijun Y. Xu‐Monette, Jianfeng Zhou, Ken H. Young

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    <i>MYC</i>-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management

    <i>MYC</i>-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management gan Qingqing Cai, L. Jeffrey Medeiros, Xiaolu Xu, Ken H. Young

    Cyhoeddwyd 2015
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms

    NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms gan Yu Li, Ling Li, L. Jeffrey Medeiros, Ken H. Young

    Cyhoeddwyd 2016
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics

    RNA-mediated immunotherapy regulating tumor immune microenvironment: next wave of cancer therapeutics gan Poonam R. Pandey, Ken H. Young, Dhiraj Kumar, Neeraj Jain

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    EBV-positive diffuse large B-cell lymphoma of the elderly

    EBV-positive diffuse large B-cell lymphoma of the elderly gan Chi Young Ok, Thomas Papathomas, L. Jeffrey Medeiros, Ken H. Young

    Cyhoeddwyd 2013
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

    Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma gan David T. Yang, Ken H. Young, Brad S. Kahl, Stephanie Markovina, Shigeki Miyamoto

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?

    PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response? gan Zijun Y. Xu‐Monette, Mingzhi Zhang, Jianyong Li, Ken H. Young

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma

    The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma gan Tingxun Lu, Jie Zhang, Zijun Y. Xu‐Monette, Ken H. Young

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Recent advances in de novo CD5<sup>+</sup> diffuse large B cell lymphoma

    Recent advances in de novo CD5<sup>+</sup> diffuse large B cell lymphoma gan Preetesh Jain, Luis Fayad, Andreas Rosenwald, Ken H. Young, Susan O’Brien

    Cyhoeddwyd 2013
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets

    Dysregulation of Cell Survival in Diffuse Large B Cell Lymphoma: Mechanisms and Therapeutic Targets gan Yi Miao, L. Jeffrey Medeiros, Zijun Y. Xu‐Monette, Jianyong Li, Ken H. Young

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: